Published in Int J Urol on June 01, 1995
Nanocarrier mediated delivery of siRNA/miRNA in combination with chemotherapeutic agents for cancer therapy: current progress and advances. J Control Release (2014) 1.32
In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients. Br J Cancer (2006) 0.96
Non-specific immunotherapy with bacille Calmette-Guérin (BCG). Clin Exp Immunol (2001) 0.84
Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer. World J Urol (2009) 0.79
Evolving immunotherapeutic strategies in bladder and renal cancer. Postgrad Med J (2004) 0.76
Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med (1991) 6.94
Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA (1993) 3.46
Characterization of fibronectin-binding antigens released by Mycobacterium tuberculosis and Mycobacterium bovis BCG. Infect Immun (1988) 3.35
Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves. J Urol (1994) 3.17
Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA (1995) 2.63
The secreted antigens of Mycobacterium tuberculosis and their relationship to those recognized by the available antibodies. J Gen Microbiol (1988) 2.38
Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol (1995) 2.05
Ultrafast thermally induced unfolding of RNase A. Proc Natl Acad Sci U S A (1995) 1.97
Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am J Pathol (1995) 1.94
Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum (2001) 1.85
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients with AIDS. A randomized, controlled trial. Ann Intern Med (1997) 1.80
Dominant expression of a distinctive V14+ T-cell antigen receptor alpha chain in mice. Proc Natl Acad Sci U S A (1991) 1.63
The effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: a further report with 7 years of follow up. J Urol (1996) 1.63
Comparison of three nonviral transfection methods for foreign gene expression in early chicken embryos in ovo. Biochem Biophys Res Commun (1997) 1.57
Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol (1999) 1.55
Randomized clinical trial on chemoprophylaxis of recurrence in cases of superficial bladder cancer. Cancer Chemother Pharmacol (1983) 1.54
Development of a mouse model for nonbacterial prostatitis. J Urol (1994) 1.53
Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J Natl Cancer Inst (1997) 1.52
Argyrophilic nucleolar organizer region in proliferating cell has a predictive value for local recurrence in superficial bladder tumor. J Urol (1999) 1.50
A Mycobacterium leprae gene encoding a fibronectin binding protein is used for efficient invasion of epithelial cells and Schwann cells. Infect Immun (1995) 1.46
Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis. J Immunol (2000) 1.45
Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. Eur Urol (1995) 1.45
Localization of a gene for an autosomal recessive form of juvenile Parkinsonism to chromosome 6q25.2-27. Am J Hum Genet (1997) 1.43
Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response. J Clin Invest (1990) 1.42
Prognostic value of cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120cas) in bladder tumors. Cancer Res (1996) 1.41
Evaluation of nucleolar organizer regions in human bladder cancers by light- and electron-microscopic morphometry. Eur Urol (1998) 1.40
Long-term results of donor-specific blood transfusion with cyclosporine in living related kidney transplantation. Nephron (2001) 1.39
Comparative study of erythrocyte deformability in maternal and cord blood. Am J Perinatol (1995) 1.38
Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells. J Clin Invest (1993) 1.38
Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA (1999) 1.38
Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J Urol (1987) 1.33
Effect of low-intensity back exercise on quality of life and back extensor strength in patients with osteoporosis: a randomized controlled trial. Osteoporos Int (2007) 1.30
Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus. Br J Cancer (2003) 1.30
Intravesical Bacillus Calmette-Guérin therapy for murine bladder tumors: initiation of the response by fibronectin-mediated attachment of Bacillus Calmette-Guérin. Cancer Res (1987) 1.28
Characterization of the fibronectin-attachment protein of Mycobacterium avium reveals a fibronectin-binding motif conserved among mycobacteria. Mol Microbiol (1996) 1.27
Effect of patient age on early detection of prostate cancer with serum prostate-specific antigen and digital rectal examination. Urology (1993) 1.23
Bacillus Calmette-Guérin and superficial bladder cancer. Clinical experience and mechanism of action. Surg Annu (1990) 1.22
Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan. Jpn J Clin Oncol (2008) 1.22
Deferred treatment of clinically localized low-grade prostate cancer: actual 10-year and projected 15-year follow-up of the Karolinska series. Urology (1997) 1.20
NK cells are essential for effective BCG immunotherapy. Int J Cancer (2001) 1.19
Anterior decompression of foraminal stenosis below a lumbosacral transitional vertebra. A case report. Spine (Phila Pa 1976) (1997) 1.18
Deferred treatment of clinically localized low grade prostate cancer: the experience from a prospective series at the Karolinska Hospital. J Urol (1994) 1.17
Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res (1991) 1.17
Quantitative analysis of serum IL-6 and its correlation with increased levels of serum IL-2R in HIV-induced diseases. J Immunol (1990) 1.16
Incidence of venous thromboembolism following major abdominal surgery: a multi-center, prospective epidemiological study in Japan. J Thromb Haemost (2006) 1.14
Resveratrol and cancer: chemoprevention, apoptosis, and chemo-immunosensitizing activities. Curr Med Chem Anticancer Agents (2003) 1.13
Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity. Clin Exp Immunol (2003) 1.12
Biological variation of total, free and percent free serum prostate specific antigen levels in screening volunteers. J Urol (1997) 1.12
Role of a bacillus Calmette-Guérin fibronectin attachment protein in BCG-induced antitumor activity. Int J Cancer (2000) 1.12
A case of intravascular papillary endothelial hyperplasia (Masson's tumor) arising from renal sinus. Jpn J Clin Oncol (1997) 1.10
Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer. J Urol (1987) 1.10
Durability of the tumor-free response for intravesical bacillus Calmette-Guerin therapy. J Urol (1994) 1.10
Embryonic development and postnatal changes in free D-aspartate and D-serine in the human prefrontal cortex. J Neurochem (1993) 1.09
The expression of pregnane X receptor and its target gene, cytochrome P450 3A1, in perinatal mouse. Mol Cell Endocrinol (2001) 1.09
Cardiovascular complications to treatment of prostate cancer with estramustine phosphate (Estracyt) or conventional estrogen. A follow-up of 212 randomized patients. Scand J Urol Nephrol Suppl (1980) 1.09
Promoting effects and mechanisms of action of androgen in bladder carcinogenesis in male rats. Eur Urol (1997) 1.09
Characterization of the fibronectin binding motif for a unique mycobacterial fibronectin attachment protein, FAP. J Biol Chem (1999) 1.08
Preliminary evaluation of fluid-attenuated inversion-recovery MR in the diagnosis of intracranial tumors. AJNR Am J Neuroradiol (1996) 1.08
Internalization of bacille Calmette-Guerin by bladder tumor cells. J Urol (1991) 1.08
A role for Pax-1 as a mediator of notochordal signals during the dorsoventral specification of vertebrae. Development (1993) 1.07
Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol (2003) 1.06
Modulation of fibronectin-mediated Bacillus Calmette-Guérin attachment to murine bladder mucosa by drugs influencing the coagulation pathways. Cancer Res (1991) 1.06
The treatment of advanced carcinoma of the bladder with a combination of adriamycin and 5-fluorouracil. Eur Urol (1977) 1.04
Stress and symptomatology in patients with interstitial cystitis: a laboratory stress model. J Urol (2000) 1.04
Single course versus maintenance bacillus Calmette-Guerin therapy for superficial bladder tumors: a prospective, randomized trial. J Urol (1987) 1.04
Tumor-specific autologous cytotoxic T lymphocytes from tissue sections. Nat Med (1996) 1.04
Effect of digital rectal examination and needle biopsy on serum total and percentage of free prostate specific antigen levels. J Urol (1997) 1.04
Diagnosis of anomalous pancreaticobiliary junction: value of magnetic resonance cholangiopancreatography. Surgery (1998) 1.03
Effect of hormonal therapy on plasma testosterone levels in prostatic carcinoma. Br Med J (1971) 1.03
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer (1998) 1.03
Leiomyosarcoma of the ovarian vein: an unusual cause of severe abdominal and flank pain. Int J Urol (1996) 1.03
Histological features of skin reactions to human lymphoid cell line lymphokine in patients with advanced cancer. J Pathol (1982) 1.03
Selectivity of TRAIL-mediated apoptosis of cancer cells and synergy with drugs: the trail to non-toxic cancer therapeutics (review). Int J Oncol (1999) 1.02
Treatment of superficial bladder tumors: achievements and needs. The EORTC Genitourinary Group. Eur Urol (2000) 1.01
Cutting edge: restoration of the ability to generate CTL in mice immune to adenovirus by delivery of virus in a collagen-based matrix. J Immunol (2001) 1.00
gamma-Interferon induced by S. aureus protein A augments natural killing and ADCC. Nature (1981) 1.00
Malignant melanoma in a woman with LEOPARD syndrome: identification of a germline PTPN11 mutation and a somatic BRAF mutation. Br J Dermatol (2007) 1.00
CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients. Leukemia (2012) 1.00
Stability of serum total and free prostate specific antigen under varying storage intervals and temperatures. J Urol (1997) 0.99
Four-hydroxyphenylpyruvic acid oxidase deficiency with normal fumarylacetoacetase: a new variant form of hereditary hypertyrosinemia. Pediatr Res (1983) 0.99
Up-regulation of MKK4, MKK6 and MKK7 during prostate cancer progression: an important role for SAPK signalling in prostatic neoplasia. J Pathol (2007) 0.99
Accuracy of digital rectal examination and transrectal ultrasonography in localizing prostate cancer. J Urol (1994) 0.99
Bicalutamide 80 mg combined with a luteinizing hormone-releasing hormone agonist (LHRH-A) versus LHRH-A monotherapy in advanced prostate cancer: findings from a phase III randomized, double-blind, multicenter trial in Japanese patients. Prostate Cancer Prostatic Dis (2007) 0.99
Lymphocyte transformation inb carcinoma of the prostate. Br J Urol (1971) 0.98
Adjuvant chemotherapy with doxorubicin (Adriamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy. Br J Urol (1983) 0.98
Sclerosing stromal tumor of the ovary: US, MR, and dynamic MR findings. J Comput Assist Tomogr (2001) 0.98
Clinical evaluation of nuclear matrix protein 22 (NMP22) in urine as a novel marker for urothelial cancer. Eur Urol (1997) 0.98
Characterization of soluble fibronectin binding to Bacille Calmette-Guérin. J Gen Microbiol (1989) 0.98
Does the use of stained maggots present a risk of bladder cancer to coarse fishermen? Carcinogenesis (1983) 0.97
Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors. Int J Cancer (2001) 0.97
Lens capsule abnormalities in Alport's syndrome. Arch Ophthalmol (1987) 0.97
Regulation of expanded polyglutamine protein aggregation and nuclear localization by the glucocorticoid receptor. Proc Natl Acad Sci U S A (2000) 0.96
Restless legs syndrome in hemodialysis patients: health-related quality of life and laboratory data analysis. Clin Nephrol (2006) 0.96
Technical factors affecting the reproducibility of intravesical mouse bladder tumor implantation during therapy with Bacillus Calmette-Guérin. Cancer Res (1984) 0.96
APC stimulated by CpG oligodeoxynucleotide enhance activation of MHC class I-restricted T cells. J Immunol (2000) 0.96
Decreased expression of alpha-catenin is associated with poor prognosis of patients with localized renal cell carcinoma. Int J Cancer (1997) 0.96
A new Pax gene, Pax-9, maps to mouse chromosome 12. Mamm Genome (1993) 0.96